NASDAQ:XBIO Xenetic Biosciences Q4 2025 Earnings Results & Report $1.40 -0.14 (-9.09%) Closing price 11/20/2026 03:47 PM EasternExtended Trading$1.46 +0.06 (+3.93%) As of 11/20/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Xenetic Biosciences beat analyst expectations on both earnings and revenue in its Q4 2025 results, released March 12, 2026. The company reported EPS of -$0.22 versus the -$0.52 consensus estimate, while revenue of $766.30 thousand topped the $690 thousand estimate by $76.30 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMarch 12, 2026TimeBefore Market OpensConference Call7:00 AM ET Xenetic Biosciences EPS ResultsActual EPS-$0.22Consensus EPS -$0.52Beat/MissBeat by +$0.30One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersXenetic Biosciences Revenue ResultsActual Revenue$766.30 thousandExpected Revenue$690 thousandBeat/MissBeat by +$76.30 thousandYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Xenetic Biosciences Q4 2025 Earnings FAQ Did Xenetic Biosciences beat earnings estimates for Q4 2025? Xenetic Biosciences (NASDAQ:XBIO) reported earnings of -$0.22 per share for Q4 2025, beating the consensus estimate of -$0.52. The report was announced on Thursday, March 12, 2026. What was Xenetic Biosciences' revenue for Q4 2025? Xenetic Biosciences reported revenue of $766.30 thousand for Q4 2025, against a consensus estimate of $690 thousand. Xenetic Biosciences Earnings HeadlinesContrasting Xenetic Biosciences (XBIO) and Its PeersNovember 20 at 4:00 AM | americanbankingnews.comXenetic Biosciences Announces Oral Presentation at 68th ASH Annual Meeting Highlighting DNase I as a Potential Strategy to Overcome CAR T-Cell ResistanceNovember 4, 2026 | finance.yahoo.comWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.November 22 at 1:00 AM | Porter & Company (Ad)Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in ...October 15, 2026 | finance.yahoo.comXenetic To Acquire Santersus In All-Stock Deal To Advance NET-Focused PipelineSeptember 17, 2026 | rttnews.comXenetic Biosciences y Santersus AG acuerdan crear un líder global en terapias contra las NETSeptember 16, 2026 | es.finance.yahoo.comSee More Xenetic Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Xenetic Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xenetic Biosciences and other key companies, straight to your email. Email Address About Xenetic BiosciencesXenetic Biosciences (NASDAQ:XBIO) is a biotechnology company focused on developing immuno-oncology treatments. Its XCART platform is designed to create personalized CAR T-cell therapies that recognize tumor-specific antigens on B-cell lymphomas, with the goal of targeting cancer cells while limiting effects on healthy cells.The company’s earlier work included PolyXen, a drug-delivery platform based on polysialic acid that was designed to extend the time biologic medicines remain in the body. Xenetic’s current stated focus is advancing its XCART technology and related product candidates.View Xenetic Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 11/16 - 11/20If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel ItZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in LimboAirfares Are Up, Flights Are Tight: 3 Airline Stocks Facing a Winter TestOwens Corning's Stock Slump May Have a Silver Lining for Dividend InvestorsThe Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity StocksHard Drives Were Left for Dead, But Seagate and Western Digital Are Soaring Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.